[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659596":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":12,"studyPopulation":12,"armGroups":19,"interventions":30,"overallOfficials":12,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":12,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":12,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":12,"overallStatus":45,"whyStopped":12,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"GuangZhou Cellgenes Biotechnology Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":12,"otherOutcomes":12},[9],{"measure":10,"description":10,"timeFrame":11},"Incidence of study-related adverse events(AE) and serious adverse events(SAE) from the first administration of CG-BM1 to 30 days after the last administration.","30 days after the last administration",null,{"allocation":14,"interventionModel":15,"interventionModelDescription":12,"primaryPurpose":16,"observationalModel":12,"timePerspective":12,"maskingInfo":17},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":12,"whoMasked":12},"NONE",[20,26],{"label":21,"type":22,"description":23,"interventionNames":24},"Experimental Group 1","EXPERIMENTAL","Paitents in Experimental Group 1 receive CG-BM1+conventional treatment. Administered procedure of CG-BM1 is 5.0 × 10\\^7 cells once a month for a total of 2 administrations.Conventional treatment includes nutritional support, symptomatic treatment, and other comprehensive care. Drug: CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection administered once monthly for a total of 2 doses.",[25],"Biological: CG-BM1",{"label":27,"type":22,"description":28,"interventionNames":29},"Experimental Group 2","Paitents in Experimental Group 1 receive CG-BM1 +Conventional treatment . Administered procedure of CG-BM1is 1.0 × 10\\^8 cells once a month for a total of 2 administrations.Conventional treatment includes nutritional support, symptomatic treatment, and other comprehensive care. Drug: CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection administered once monthly for a total of 2 doses.",[25],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":12},"BIOLOGICAL","CG-BM1","Intravenous infusion, once monthly for a total of 2 administrations.",[21,27],[37],{"name":38,"role":39,"phone":40,"phoneExt":12,"email":41},"Zeng Liping, Senior Medical Director","CONTACT","+86 20 82514048","Ip.zeng@cellgenes.com",[43],{"facility":44,"status":45,"city":46,"state":12,"zip":12,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Guangdong Provincial People's Hospital","RECRUITING","Guangzhou","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":57,"role":39,"phone":58,"phoneExt":12,"email":59},"Xue Yumei, Chief Physician","+86 13570082363","xymgdci@163.com",{"type":61,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100659596","phase-1-clinical-trial-of-cg-bm1-allogeneic-human-bone-marrow-mesenchymal-stem-cell-injection-in-the-treatment-of-sarcopenia-100659596",false,"NCT07865676","Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia","An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia","CGBM1-SAR-01","Inclusion Criteria:\n\n* 1\\. Voluntary participation; participant or legal guardian fully understands the study and provideswritten informed consent; participant is willing and able to comply with all study procedures.\n\n  2.Male or female, aged ≥50 to \\\u003C85 years at screening. 3.Meets the Asian Working Group for Sarcopenia (AWGS) 2025 diagnostic criteria for sarcopenia.\n\n  4\\. Body weight \\>35 kg and unwilling or unable to perform regular resistance exercise training during the study.\n\n  5.Male participants must agree not to father a child, and female participants must not be pregnant or breastfeeding; female participants of childbearing potential must use effective contraception. These requirements apply from informed consent through the final visit.\n\nExclusion Criteria:\n\n* 1\\. Known hypersensitivity to any component of CG-BM1 (human bone marrow mesenchymal stem cells; excipients include dimethyl sulfoxide and human serum albumin).\n\n  2\\. Regular use of growth hormone or steroid hormones (e.g., androgens, estrogens,glucocorticoids) within 3 months before screening; inhaled glucocorticoids and vitamin D are permitted.\n\n  3\\. Severe systemic disease, including but not limited to NYHA Class III-IV heart failure; end-stage lung disease; renal impairment with eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²; Child-Pugh Class C hepatic impairment; severe gastrointestinal disease or inability to eat normally; severe infection; or prolonged bed rest.\n\n  4\\. Neurological disability, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke sequelae (e.g., muscle weakness or gait abnormality), or dementia.\n\n  5.History of malignancy. 6. Pulmonary embolism within 3 months before screening or deep vein thrombosis at screening;low-risk intermuscular venous thrombosis is permitted.\n\n  7.Previous stem cell therapy. 8. Participation in another interventional clinical trial within 3 months or 5 half-lives (for investigational drug interventions; whichever is longer) before study drug infusion.\n\n  9.Any other condition that, in the investigator's opinion, makes the participant unsuitable for this trial.","ALL","50 Years","85 Years",{"count":74,"type":75},30,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE1","PHASE2","1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Sarcopenia.\n2. To observe the preliminary effectiveness of CG-BM1 in treating Sarcopenia patients.",[82],"Sarcopenia","2026-10-03",{"date":85,"type":86},"2026-10-08","ACTUAL",{"date":88,"type":86},"2026-04-30",{"date":90,"type":75},"2029-10-31",{"name":5,"class":6},1]